On June 13-14, 2018, in Boston, Massachusetts, Ncardia will host its Annual U.S. User Symposium. The event will showcase the use of Ncardia’s flagship hiPSC-derived cardiac models (Cor.4U® and Pluricyte®) and its hiPSC-derived neural cell products by key leaders in pharma and research.
Importantly, it will explore how experts in the pharmaceutical and biotechnology industry and leading academic institutions are using Ncardia’s first in class cells and assays in drug discovery, safety and toxicology screening, disease modelling and bioengineering. It will also present current approaches to establish and define standards for these cellular models.
Expected to be widely attended by representatives from the pharmaceutical sector, symposium attendees will view case studies of iPS cells in drug development decision-making and biomedical research and have the opportunity to exchange and share experiences with their peers.